Skip to content

Application of Autofluorescence Imaging in Robotic Thyroid Surgery

Application of Autofluorescence Imaging in Robotic Thyroid Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122094
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid carcinoma

Interventions

Experimental group:Autofluorescence and indocyanine green imaging were used to identify and protect parathyroid glands during robotic thyroid surgery.
Control group:Conventional naked-eye identification was used to identify and protect parathyroid glands during robotic thyroid surgery.

Sponsors

The 960th Hospital of the Joint Support Force of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years, able to understand and sign the informed consent form. 2. Patients undergoing initial surgery with suspected thyroid cancer indicated by neck ultrasound, computed tomography (CT), and fine-needle aspiration cytology (FNAC). 3. Preoperative parathyroid hormone (PTH)and serum calcium levels within normal ranges. 4. Scheduled to undergo robotic total thyroidectomy with unilateral or bilateral central lymph node dissection. 5. Complete clinical data available.

Exclusion criteria

Exclusion criteria: 1. Inability to sign the informed consent form. 2. History of previous neck surgery. 3. Patients with unilateral thyroid cancer undergoing unilateral lobectomy. 4. Patients with hyperparathyroidism or concomitant parathyroid tumors. 5. Patients with thyroid tumors invading surrounding organs and tissues (e.g., trachea, esophagus) indicated by auxiliary examinations, in whom radical resection cannot be achieved surgically. 6. Patients with severe hepatic or renal insufficiency, coagulation disorders, or other diseases that preclude tolerance to surgery, as well as those with contraindications to iodine-related contrast agents.

Design outcomes

Primary

MeasureTime frame
Number of parathyroid glands identified intraoperatively;Serum parathyroid hormone (PTH) level on postoperative day 1;Serum calcium (Ca) level on postoperative day 1;

Secondary

MeasureTime frame
Operation duration;Postoperative complications;

Countries

China

Contacts

Public ContactHe Qingqing

The 960th Hospital of the Joint Support Force of the People's Liberation Army of China

heqingqing@yeah.net+86 137 8982 6586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026